Prostate Cancer | Specialty

AR-V7 Testing in mCRPC

June 26th 2017

Sequencing and Layering of Drugs in CRPC

June 26th 2017

Radiation Therapy and ADT in CRPC

June 26th 2017

Abiraterone and Chemotherapy in CRPC

June 26th 2017

Combination Therapies in Localized Prostate Cancer

June 26th 2017

Active Surveillance in Prostate Cancer

June 26th 2017

Molecular Testing in Prostate Cancer

June 26th 2017

Genetic Testing in Prostate Cancer

June 26th 2017

Heritable Prostate Cancer: Germline vs Somatic Mutations

June 26th 2017

Active Surveillance Retains Critical Role in Prostate Cancer Care

June 26th 2017

Andrew Stephenson, MD, discusses some of the past and current data demonstrating the benefits of active surveillance for patients with localized prostate cancer and the evolving opinions on PSA screening.

Uses of MRI Testing in Prostate Cancer

June 23rd 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses some potential uses of MRI testing for patients with prostate cancer.

Dr. Stephenson on the Impact of Active Surveillance in Prostate Cancer

June 23rd 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses the impact of active surveillance on the field of prostate cancer.

Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

June 23rd 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

Feasibility Results Support Launching Full Phase III PART Trial in Prostate Cancer

June 22nd 2017

Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation with radical prostatectomy in patients with intermediate-risk prostate cancer.

Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene

June 22nd 2017

Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.

How Urology Clinics of North Texas Is Overcoming Payment Challenges

June 21st 2017

As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.

Recent Patterns Indicate PSA Testing Halt in Decline

June 20th 2017

A recent nationally representative study published in JAMA Internal Medicine found that previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.

Dr. Chi on Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Naive Prostate Cancer

June 20th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses androgen deprivation therapy (ADT) with abiraterone acetate (Zytiga) plus prednisone or placebo in patients with high-risk metastatic hormone-naïve prostate cancer.

Deeper Understanding Leading to Better Care for Patients With Prostate Cancer

June 17th 2017

Although the past few months have seen several androgen receptor resistance, and described drug approvals for bladder cancer therapies, a wealth of research also is moving the field of prostate cancer forward, since gaining a better understanding of the disease is the best way to find out how to optimally treat—and perhaps ultimately cure—prostate cancer.

Benefit Confirmed for ERBT Plus ADT in Locally Advanced Prostate Cancer

June 14th 2017

The addition of external beam radiation therapy to ADT reduced the risk of disease progression more than 70% compared with ADT alone among patients with locally advanced prostate cancer.